RAGE supports parathyroid hormone-induced gains in femoral trabecular bone

American Journal of Physiology - Endocrinology and Metabolism

Volumn 298, Issue 3, 2010, Pages

  Philip, Binu K ^a   Childress, Paul J ^a   Robling, Alexander G ^a,b   Heller, Aaron ^a   Nawroth, Peter P ^c   Bierhaus, Angelika ^c   Bidwell, Joseph P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anabolic; High mobility group box 1 protein; Osteoblast; Osteoimmunology; Osteoporosis; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; FATTY ACID BINDING PROTEIN 4; LYMPHOID ENHANCER FACTOR 1; NUCLEAR MATRIX PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY FAT DISTRIBUTION; BONE DENSITY; BONE MASS; BONE MINERAL; CANCELLOUS BONE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FEMUR SHAFT; GENE DELETION; GENE EXPRESSION REGULATION; GENE SILENCING; HORMONAL THERAPY; HORMONE RESPONSE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; SPINE; TIBIA; TISSUE STRUCTURE; TRABECULAR BONE;

ANIMALS; BONE DENSITY; BONE DEVELOPMENT; CALCIFICATION, PHYSIOLOGIC; FEMALE; FEMUR; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; PARATHYROID HORMONE;

EID: 77349111934     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00564.2009     Document Type: Article

References (38)

1. Allen MR, Burr DB. Parathyroid hormone and bone biomechanics. Clin Rev Bone Miner Metab 4: 259-268, 2006.
2. Bagi CM, Brommage R, Deleon L, Adams S, Rosen D, Sommer A. Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J Bone Miner Res 9: 1301-1312, 1994.
3. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 7: 985-991, 2006.
4. Bidwell JP, Yang J, Robling AG. Is HMGB1 an osteocyte alarmin? J Cell Biochem 103: 1671-1680, 2008.
5. Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs 68: 2709-2737, 2008.
6. Boyce RW, Paddock CL, Franks AF, Jankowsky ML, Eriksen EF. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 11: 600-613, 1996.
7. Chung DJ, Castro CH, Watkins M, Stains JP, Chung MY, Szejnfeld VL, Willecke K, Theis M, Civitelli R. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci 119: 4187-4198, 2006.
8. Constien R, Forde A, Liliensiek B, Gröne HJ, Nawroth P, Hämmerling G, Arnold B. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30: 36-44, 2001.
9. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetić K, Müller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16: 1846-1853, 2001.
10. Ding M, Hvid I. Quantification of age-related changes in the structure model type and trabecular thickness of human tibial cancellous bone. Bone 26: 291-295, 2000.
11. Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang B, Yan SL, She JX, Stern DM, Isales CM, Mi QS. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 340: 1091-1097, 2006.
12. Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 113: 154-161, 2007.
13. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 473: 218-224, 2008.
14. Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 40: 391-398, 2007.
15. Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17: 808-816, 2002.
16. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28: 150-159, 2001.
17. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40: 1434-1446, 2007.
18. Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 282: 14515-14524, 2007.
19. Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol 5: 365-372, 2009.
20. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050-5055, 2001.
21. Kulkarni NH, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, N'cho M, Sterchi DL, Gitter BD, Higgs RE, Halladay DL, Engler TA, Martin TJ, Bryant HU, Ma YL, Onyia JE. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J Cell Biochem 102: 1504-1518, 2007.
22. Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM, Schmidt AM. Blockade of RAGE suppresses periodontitis- associated bone loss in diabetic mice. J Clin Invest 105: 1117-1124, 2000.
23. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144: 2008-2015, 2003.
24. McCabe LR. Switching fat from the periphery to bone-why in type I diabetes? Expert Rev Endocrinol Metab 4: 203-207, 2009.
25. Nakashima T, Takayanagi H. The dynamic interplay between osteoclasts and the immune system. Arch Biochem Biophys 473: 166-171, 2008.
26. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation endproducts (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 39: 871-875, 2007.
27. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15: 16R-28R, 2005.
28. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 280: 1340-1344, 1980.
29. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20: 177-184, 2005.
30. Robling AG, Childress P, Yu J, Cotte J, Heller A, Philip BK, Bidwell JP. Nmp4/CIZ suppresses parathyroid hormone-induced increases in trabecular bone. J Cell Physiol 219: 734-743, 2009.
31. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7: 17, 2009.
32. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 328: 688-696, 2005.
33. Taniguchi N, Yoshida K, Ito T, Tsuda M, Mishima Y, Furumatsu T, Ronfani L, Abeyama K, Kawahara K, Komiya S, Maruyama I, Lotz M, Bianchi ME, Asahara H. Stage-specific secretion of HMGB1 in cartilage regulates endochondral ossification. Mol Cell Biol 27: 5650-5663, 2007.
34. Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, Qu W, Lincoff AM, Schmidt AM, Topol EJ, Penn MS. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 317: 37-43, 2006.
35. Xiao Z, Awad HA, Liu S, Mahlios J, Zhang S, Guilak F, Mayo MS, Quarles LD. 2005 Selective Runx2-II deficiency leads to low-turnover osteopenia in adult mice. Dev Biol 283: 345-356.
36. Yang J, Shah R, Robling AG, Templeton E, Yang H, Tracey KJ, Bidwell JP. HMGB1 is a bone-active cytokine. J Cell Physiol 214: 730-739, 2008.
37. Zhou Z, Han JY, Xi CX, Xie JX, Feng X, Wang CY, Mei L, Xiong WC. HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE. J Bone Miner Res 23: 1084-1096, 2008.
38. Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L, Nawroth P, Stern DM, Xiong WC. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 203: 1067-1080, 2006.